RECRUITING

MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows a single bout of ischemic conditioning or oral ingestion of an over-the-counter antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.

Official Title

MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes (MITO Study)

Quick Facts

Study Start:2025-07-22
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06930638

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18 - 85 years of age
  2. * Cortical or sub-cortical stroke ≥ 6 months ago with residual hemiparesis
  3. * Able to give informed consent and follow 2-step command.
  4. * English Speaking
  1. * Unable to stand from chair without physical assistance from another person (able to use assistive device).
  2. * History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg).
  3. * Chronic lasting symptoms (\> 6 months) of severe COVID-19 (i.e., hospitalization)
  4. * History of head trauma or concussion within the past 6 months
  5. * Comorbid neurological disorder
  6. * Peripheral vascular disease
  7. * Myocardial infarction or arrhythmia in the previous year
  8. * Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg
  9. * Pregnant or breastfeeding.
  10. * Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator

Contacts and Locations

Study Contact

Jennifer Nguyen
CONTACT
414-955-5713
jnguyen@mcw.edu
Alicen Whitaker-Hilbig, DPT, PhD
CONTACT
414-955-5713
awhitakerhilbig@mcw.edu

Principal Investigator

Matthew Durand, PhD
PRINCIPAL_INVESTIGATOR
Medical College of Wisconsin

Study Locations (Sites)

Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
United States

Collaborators and Investigators

Sponsor: Medical College of Wisconsin

  • Matthew Durand, PhD, PRINCIPAL_INVESTIGATOR, Medical College of Wisconsin

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-07-22
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2025-07-22
Study Completion Date2026-12-31

Terms related to this study

Keywords Provided by Researchers

  • Ischemic Conditioning
  • Blood Flow
  • Microvascular Health
  • Flow-Mediated Dilation
  • Antioxidant
  • Reactive Oxygen Species
  • Supplement

Additional Relevant MeSH Terms

  • Stroke